PepGen slumps after pausing mid-stage study of Duchenne drug

Shares of Boston-based drug developer PepGen PEPG.O fall 9% to $2.56 premarket

Company says it will temporarily pause mid-stage study of PGN-EDO51 in patients with Duchenne muscular dystrophy (DMD)

Says the study is paused until company can review results from patient group dosed with 10 mg/kg, which is expected during Q3

DMD is a genetic disorder causing progressive muscle weakness and degeneration

Company says no new safety issues related to PGN-EDO51 have been observed since the company's last safety update in January

PEPG has fallen 83% in the last 12 months